Asymmetric depth-filtration: A versatile and scalable method for high-yield isolation of extracellular vesicles with low contamination.

We developed a novel asymmetric depth filtration (DF) approach to isolate extracellular vesicles (EVs) from biological fluids that outperforms ultracentrifugation and size-exclusion chromatography in purity and yield of isolated EVs. By these metrics, a single-step DF matches or exceeds the performance of multistep protocols with dedicated purification procedures in the isolation of plasma EVs. We demonstrate the selective transit and capture of biological nanoparticles in asymmetric pores by size and elasticity, low surface binding to the filtration medium, and the ability to cleanse EVs held by the filter before their recovery with the reversed flow all contribute to the achieved purity and yield of preparations.

Involvement of transforming growth factor β and its type 1 receptor in the development of breast cancer.

Introduction of recent achievements of molecular biology into clinical practice contributes significantly to both prevention and early detection of breast cancer in women and development of new approaches, including genotyping, to screening for breast cancer. Screening for genetic polymorphisms in genes TGFβ1 and TGFβR1 reveals carriers of sporadic breast cancer. This provides an opportunity to reassess the role and place of preventive measures, also including surgical method, in the fight against breast cancer.

[Neoadjuvant therapy of breast cancer using Newcastle disease virus].

The role of Newcastle disease virus and neoadjuvant therapy was assessed in 84 cases of breast cancer T1-4N0-2M0 (2005-2008). Combined use of the virus vaccine and chemotherapy (group A), therapy with the vaccine alone (group B) and chemotherapy regimen identical with that used in group A (group C) were compared. Histological pattern of tumor and stage were identified using expression of receptors of steroid hormones, oncoproteins Her2/neu and p53 as well as proliferation activity (marker Ki-67) before and after therapy.

[Live xenogenic vaccine in the prevention of metastases of uveal melanoma].

By the results of experimental studies and by being guided by Protocol No. 22 dated January 22, 2004, by the Ministry of Health of the Russian Federation, the authors have conducted clinical trials of biotherapy used in oncological care. They describe the first experience in using xenovaccination in 35 patients with uveal melanoma to prevent hematogenic metastases.

[Results of combined radiotherapy of choroid melanomas].

Method of combined radiotherapy of choroid melanomas, proposed by the authors, includes transscleral irradiation of the tumor by rutenium ophthalmoapplicators and simultaneous intracorporeal irradiation with 59Fe. Twenty-seven patients were treated. Morphological examination of enucleated eyes showed the capacity of 57Fe to incorporate in tumor cell, and observations indicate that this method of treatment not only extends the indications for organ-sparing radiotherapy of uveal melanomas, but delays the development of distant metastases as well.